Mainz BioMed NV Stock Quote MYNZ - Stock Price, News, Charts, Message Board, Trades

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Current Price

0.5687

Bid

0.562

Ask

0.583

Volume

184,796

0.56 Day's Range 0.61951

0.56 52 Week Range 6.00

Market Cap

Previous Close

0.581

Open

0.5736

Last Trade

1000

0.5687

(formt)

Last Trade Time

Financial Volume

$ 105,497

VWAP

0.570882

Average Volume (3m)

119,237

Shares Outstanding

14,830,000

Dividend Yield

PE Ratio

Earnings Per Share (EPS)

Revenue

Net Profit

Mainz Biomed BV is engaged in developing molecular genetic diagnostic solutions for life-threatening conditions. It's main product Coloalert is a kit that includes a stool collector and shipping instructions to return the kit through regular mail to their local lab for testing and results. Mainz Biomed BV is engaged in developing molecular genetic diagnostic solutions for life-threatening conditions. It's main product Coloalert is a kit that includes a stool collector and shipping instructions to return the kit through regular mail to their local lab for testing and results.

Sector

Testing Laboratories

Industry

Testing Laboratories

Website

www.mainzbiomed.com

Headquarters

Amsterdam, North Holland, Nld

Founded

1970

Mainz BioMed NV is listed in the Testing Laboratories sector of the NASDAQ with ticker MYNZ. The last closing price for Mainz BioMed NV was $0.58. Over the last year, Mainz BioMed NV shares have traded in a share price range of $ 0.56 to $ 6.00.

Mainz BioMed NV currently has 14,830,000 shares outstanding.

Mainz Biomed Awarded Poster of Distinction at Digestive Disease Week, Positioning the Company for its Planned FDA Trial

Mainz Biomed Presented Industry Leading Results: 97% Sensitivity for Colorectal Cancer, 82% for Advanced Precancerous Lesions The eAArly DETECT results demonstrated that within the advanced...

Form D/A - Notice of Exempt Offering of Securities: [Amend]

Mainz Biomed to Present Results of Colorectal Cancer Screening Study eAArly DETECT at Digestive Disease Week 2024 in Washington, D.C.

BERKELEY, Calif. and MAINZ, Germany, May 07, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ), a molecular genetics diagnostic company specializing in the early detection of cancer, will...

Mainz Biomed Reports Positive Topline Results from Pooled Study Evaluating Novel mRNA Biomarkers and Proprietary AI Algorithm for Integration into Pivotal FDA PMA Clinical Trial for Next Generation Colorectal Cancer Diagnostic

Groundbreaking topline results demonstrated sensitivity for colorectal cancer of 92% with specificity of 90% and best-in-class sensitivity for advanced adenoma of 82%690 subjects analyzed...

Mainz Biomed Reports Full Year 2023 Financial Results

BERKELEY, Calif. and MAINZ, Germany, April 09, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a leader in molecular genetics diagnostic solutions for...

Mainz Biomed Organizes HALLO DOC! Event to Highlight Innovations in Colorectal Cancer Treatment

BERKELEY, Calif. and MAINZ, Germany, March 19, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a leader in molecular genetics diagnostic solutions for...

Mainz Biomed: Webinar on Early Detection of Colorectal Cancer - Exploring New Laboratory Diagnostic Options

BERKELEY, Calif. and MAINZ, Germany, March 18, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a leader in molecular genetics diagnostic solutions for...

Mainz Biomed Presents ColoAlert® at UDH Congress 2024: Leading the Way in Evidence-Based Cancer Screening Innovations

BERKELEY, Calif. and MAINZ, Germany, March 12, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a leader in molecular genetics diagnostic solutions for...

Mainz Biomed Partners with Trusted Health Advisors to Support U.S. Go-To-Market Strategy for Next Generation Early Colorectal Cancer Diagnostic

Dr. Jay Wohlgemuth, former Chief Medical & Scientific Officer of Quest Diagnostics and Dr. Ray Tabibiazar, a seasoned industry executive, to lead collaborationMainz Biomed’s Pivotal FDA PMA...

Mainz Biomed to Showcase at the Gynecology Conference in Stuttgart, Germany, Strengthening Connections within the Medical Community

BERKELEY, Calif. and MAINZ, Germany, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a leader in molecular genetics diagnostic solutions for...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.0623	-9.87321711569	0.631	0.71	0.56	201413	0.62676339	CS
4	-0.3193	-35.9572072072	0.888	1.08	0.56	220185	0.75529238	CS
12	-0.3313	-36.8111111111	0.9	1.14	0.56	119237	0.84438396	CS
26	-0.6113	-51.8050847458	1.18	1.79	0.56	161397	1.06005259	CS
52	-4.5213	-88.8271119843	5.09	6	0.56	133448	1.87418946	CS
156	-13.7813	-96.0369337979	14.35	30	0.56	139784	9.33092663	CS
260	-13.7813	-96.0369337979	14.35	30	0.56	139784	9.33092663	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
AKTSAkoustis Technologies Inc	$ 0.3151 (128.83%)	542.87M
BCGBinah Capital Group Inc	$ 4.22 (56.30%)	2.17M
IGMSIGM Biosciences Inc	$ 11.48 (36.50%)	3.18M
GWAVGreenwave Technology Solutions Inc	$ 0.0788 (33.79%)	1.54B
ISPCiSpecimen Inc	$ 0.317501 (29.20%)	11.82M
EDBLEdible Garden AG Inc	$ 2.25 (-48.04%)	5.64M
BDRXBiodexa Pharmaceuticals PLC	$ 1.295 (-44.42%)	10.53M
HYWHywin Holdings Ltd	$ 0.486 (-30.56%)	295.14k
MTCMMTec Inc	$ 0.6215 (-30.17%)	25.3M
NBSTWNewbury Street Acquisition Corporation	$ 0.0699 (-30.10%)	777
GWAVGreenwave Technology Solutions Inc	$ 0.0788 (33.79%)	1.54B
AKTSAkoustis Technologies Inc	$ 0.3151 (128.83%)	542.87M
CRKNCrown Electrokinetics Corporation	$ 0.1282 (1.99%)	531.12M
FFIEFaraday Future Intelligent Electric Inc	$ 1.12 (-19.42%)	204.13M
BRSHBruush Oral Care Inc	$ 0.1493 (26.85%)	198.23M